Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
make a formal presentation session to investors at the Deutsche Bank 41st
Annual Healthcare Conference on May 4, 2016 at 8:00 a.m. ET.
A live webcast and replay of the presentation will be accessible by
visiting the “Calendar of Events” section on the “Investors” page of
Enanta’s website at www.enanta.com.
The replay webcast will be available following the presentation and will
be archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta’s
research and development is currently focused on four disease targets:
Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic
Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).
Enanta has discovered novel protease inhibitors and NS5A inhibitors that
are members of the direct-acting-antiviral (DAA) inhibitor classes
designed for use against the hepatitis C virus (HCV). Enanta’s protease
inhibitors, developed through its collaboration with AbbVie, include
paritaprevir, which is contained in AbbVie’s marketed DAA regimens for
HCV, and ABT-493, Enanta’s second protease inhibitor, which AbbVie is
developing in phase 3 studies in combination with ABT-530, AbbVie’s NS5A
inhibitor. Enanta has also discovered a cyclophilin inhibitor, EDP-494,
a novel host-targeting mechanism for HCV, which is now in phase 1
clinical development, and EDP-305, an FXR agonist, which Enanta plans to
advance into clinical development for NASH later in 2016. Please visit www.enanta.com
for more information on our programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160426005202/en/
Copyright Business Wire 2016